Beyond Fertility: Emerging Non-ART Applications for HCG and FSH

While assisted reproductive technology remains the primary driver of gonadotropin demand, non-ART applications are gaining attention. HCG is increasingly used in sports medicine and hormone replacement therapy for hypogonadism. FSH is being studied for its role in spermatogenesis and even certain neurological conditions. These emerging uses could expand the total addressable market for gonadotropin APIs, benefiting both urinary and recombinant suppliers. For crude and intermediate providers, diversification of end-user industries reduces reliance on the ART segment alone.